| Similar Articles |
|---|
 |
The Motley Fool
August 27, 2009
Brian Orelli |
Elan and J&J, Sitting in a Tree ... Johnson & Johnson dumps Alkermes for its new best bud in favor of Elan   |
The Motley Fool
May 9, 2011
Brian Orelli |
In Biotech, Two Platforms Are Better Than One Alkermes has swooped in and agreed to buy Elan Drug Technology for around $960 million. |
The Motley Fool
August 27, 2008
Brian Orelli |
Another FDA Setback for Johnson & Johnson The company has to wait for an approval of its extended-release schizophrenia drug. Investors, take note. |
The Motley Fool
December 14, 2009
Brian Orelli |
Finally Released From an Extended Review The FDA finally approves extended-release Zyprexa. |
The Motley Fool
October 22, 2009
Brian Orelli |
Elan's Headed in the Right Direction Revenue up, costs down. It's a good direction for Elan to take, even if the company's final earnings number was slightly inflated. |
The Motley Fool
February 29, 2008
Brian Lawler |
FDA Floors Eli Lilly Eli Lilly receives an especially harsh rebuke from the FDA about one of its top candidates when the agency refused to approve a long-lasting injection version of its multibillion-dollar Zyprexa for schizophrenia and bipolar disorder. |
The Motley Fool
August 10, 2010
Brian Orelli |
Elan's Alternative to Strategic Alternatives Sometimes doing nothing is the best option. |
The Motley Fool
September 4, 2009
Brian Orelli |
The Billion-Dollar Lovers' Quarrel Continues Elan had better bring candy and flowers to patch this up. |
The Motley Fool
February 11, 2010
Brian Orelli |
Blockbuster in Hand, It's Time to Show a Profit Elan predicts an operating profit for the first time in nine years. |
The Motley Fool
August 4, 2010
Mac Greer |
One Biotech Stock Ready to Rebound? One of our analysts gives you his thoughts on Elan. |
The Motley Fool
September 15, 2009
Brian Orelli |
What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri. |
The Motley Fool
August 7, 2009
Brian Orelli |
A Billion-Dollar Lovers' Quarrel It looks like the triangle between partners Elan and Biogen Idec and third-wheel Johnson & Johnson over the multiple sclerosis drug Tysabri is going to get settled in court. |
The Motley Fool
August 17, 2010
Brian Orelli |
Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard. |
The Motley Fool
December 28, 2010
Brian Orelli |
No Guts, No Glory For better or worse, Elan gains full control of Alzheimer's drug ELND005. |
The Motley Fool
April 21, 2011
Brian Orelli |
Tysabri Means Everything to Biogen and Elan ... for Now It's rare to find a drug that affects two companies as much as Tysabri does Biogen Idec and Elan. |
The Motley Fool
May 26, 2011
Brian Orelli |
Intriguing, Potentially Lucrative, But Still Not Worth the Jump in Shares Elan sets up a drug development deal with Proteostasis. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
February 24, 2010
Brian Orelli |
A Profitable One-Drug Wonder! It's kind of impressive that Onyx Pharmaceuticals has made a profit two years in a row: $0.03 per share in 2008, and a much healthier $0.27 per share last year. |
The Motley Fool
February 7, 2005
Brian Gorman |
Alkermes Is Coming of Age The drug delivery company may soon have its own drug on the market. |
The Motley Fool
February 11, 2009
Brian Orelli |
The FDA's Bipolar Decision Johnson & Johnson announces that the FDA has asked for more information before approving its application to market Risperdal Consta for frequently relapsing bipolar disorder. |
The Motley Fool
January 8, 2009
Brian Orelli |
FDA Toys With Lilly, and Investors, Again Eli Lilly will have to wait a little longer. |
The Motley Fool
October 8, 2008
Brian Orelli |
Lilly Gets Off Easy The company settles marketing issues over Zyprexa with 32 states. |
The Motley Fool
February 9, 2011
Brian Orelli |
Once a Decade Isn't Enough, Elan Elan posts its first operating profit in 10 years. |
The Motley Fool
September 23, 2009
Robert Steyer |
Alkermes Needs Some Financial Alchemy After a string of research and marketing disappointments, the company's CEO departs. |
The Motley Fool
July 2, 2009
Brian Orelli |
Squeezing Blood From a Half-Dollar Johnson & Johnson is investing $1 billion in Elan in exchange for an 18.4% stake in the company. |
The Motley Fool
May 19, 2009
Brian Orelli |
Flip-Flopping: Not Just for Politicians Anymore The FDA's change is good for companies. |
The Motley Fool
March 20, 2008
Brian Lawler |
The AIR's Knocked Out of Alkermes Drug developer Alkermes initiates a round of cost-cutting. |
The Motley Fool
June 11, 2007
Brian Lawler |
More Air for Alkermes The biopharmaceutical drug delivery expert brings another drug into clinic stage testing. Investors, take note. |
The Motley Fool
October 28, 2011
Brian Orelli |
Focus on Profits, Biotech Investors Elan is in the black and looking as healthy as ever. |
The Motley Fool
April 21, 2010
Brian Orelli |
Yawn! Get Back to Me Next Quarter, J&J There's more stagnant growth from the health-care giant. |
The Motley Fool
December 19, 2011
Brian Orelli |
Elan Turns It Around in 2011 Let's hope next year is as productive. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
The Motley Fool
November 24, 2009
Brian Orelli |
4 Platform Drugmakers to Invest In Elan ... Alkermes... Flamel Technologies... etc. |
The Motley Fool
September 30, 2009
Brian Orelli |
More Questions Than Answers From Elan Things that make you go hmmm. |
The Motley Fool
October 13, 2009
Brian Orelli |
J&J Needs to Get Drugged Up Medical devices and diagnostics pass by drugs as the main revenue source. |
The Motley Fool
September 14, 2009
Brian Orelli |
The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri. |
The Motley Fool
May 12, 2009
Brian Orelli |
Another Reason to Hate Big Pharma's M&A As we get closer to Pfizer and Merck wrapping up their deals, it looks like a new group is voicing their displeasure: external partners. |
The Motley Fool
October 22, 2007
Brian Lawler |
Modest Numbers From Eli Lilly Its sales were up for the quarter, but a new drug might be the best indicator of its prospects. Lilly's pipeline will dictate its near-term future. |
The Motley Fool
August 10, 2005
Jack Uldrich |
Does NanoCrystal Ball See All? There is promise in biotech Elan, but not for the reason you might think. Investors, take note. |
Chemistry World
August 9, 2012 |
Bapineuzunab dropped Pfizer and Johnson and Johnson have announced that they are ending development of the intravenous Alzheimer's drug bapineuzumab after it failed in two clinical trials. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
The Motley Fool
November 9, 2010
Brian Orelli |
Forget R&D; Buy Your Way Into Diagnostics Eli Lilly is expanding its diagnostics business by picking up privately held Avid Radiopharmaceuticals. |
The Motley Fool
January 5, 2010
Brian Orelli |
Lilly's Effient: Cheap Enough, for Now In order to justify the use of Effient, Eli Lilly is touting a study published in today's Circulation demonstrating the cost effectiveness of Effient over Plavix. |
The Motley Fool
July 21, 2010
Brian Orelli |
Biogen Looks Good Now, but What About Tomorrow? Biogen Idec saw revenue increase 11% and adjusted earnings per share jump almost 75%, which is all well and good, but the longer-term prospects for the company aren't nearly as impressive. |
The Motley Fool
September 27, 2010
Brian Orelli |
This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time. |
The Motley Fool
August 24, 2007
Brian Orelli |
Kids, Take Your Psychoactives J&J gains pediatric approval of its antipsychotic drug. Investors, take note. |
The Motley Fool
October 13, 2010
Brian Orelli |
Don't Get Addicted to Alkermes' Low Revenue Vivitrol's launch and the approval of Bydureon will drive revenue -- and Alkmeres' stock price -- in the future. |
The Motley Fool
September 30, 2010
Brian Orelli |
Avoid This Multibillion-Dollar Market It's just too crowded, but there's no doubt that psychiatric drugs are big business for some drugmakers. |
The Motley Fool
January 28, 2010
Brian Orelli |
Only the Strong Survive at Pfizer The culling of the pipeline isn't as bad as it sounds. |
The Motley Fool
July 23, 2009
Brian Orelli |
The Slowly Wilting Lilly Nothing can save this drug company. |
